Basilea Pharmaceutica Stock Forecast, Price & News

0.00 (0.00 %)
(As of 09/15/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Average VolumeN/A
Market Capitalization$494.04 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive BPMUF News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

Basilea Pharmaceutica logo

About Basilea Pharmaceutica

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include Cresemba, Zevtera, Derazantinib, BAL101553, and BAL3833. The company was founded on October 17, 2000 and is headquartered in Basel, Switzerland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.95 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Basilea Pharmaceutica (OTCMKTS:BPMUF) Frequently Asked Questions

Is Basilea Pharmaceutica a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Basilea Pharmaceutica in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Basilea Pharmaceutica stock.
View analyst ratings for Basilea Pharmaceutica
or view top-rated stocks.

What stocks does MarketBeat like better than Basilea Pharmaceutica?

Wall Street analysts have given Basilea Pharmaceutica a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Basilea Pharmaceutica wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Basilea Pharmaceutica's stock price been impacted by COVID-19 (Coronavirus)?

Basilea Pharmaceutica's stock was trading at $44.30 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BPMUF stock has increased by 3.8% and is now trading at $46.00.
View which stocks have been most impacted by COVID-19

Who are Basilea Pharmaceutica's key executives?

Basilea Pharmaceutica's management team includes the following people:
  • David Veitch, Chief Executive Officer
  • Adesh Kaul, Chief Financial Officer
  • Laurenz Kellenberger, Chief Scientific Officer
  • Marc Engelhardt, Chief Medical Officer
  • Gerrit Hauck, Chief Technology Officer

Who are some of Basilea Pharmaceutica's key competitors?

What is Basilea Pharmaceutica's stock symbol?

Basilea Pharmaceutica trades on the OTCMKTS under the ticker symbol "BPMUF."

How do I buy shares of Basilea Pharmaceutica?

Shares of BPMUF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Basilea Pharmaceutica's stock price today?

One share of BPMUF stock can currently be purchased for approximately $46.00.

How much money does Basilea Pharmaceutica make?

Basilea Pharmaceutica has a market capitalization of $494.04 million and generates $136.11 million in revenue each year. The company earns $-15,700,000.00 in net income (profit) each year or ($1.53) on an earnings per share basis.

How many employees does Basilea Pharmaceutica have?

Basilea Pharmaceutica employs 157 workers across the globe.

What is Basilea Pharmaceutica's official website?

The official website for Basilea Pharmaceutica is www.basilea.com.

Where are Basilea Pharmaceutica's headquarters?

Basilea Pharmaceutica is headquartered at Grenzacherstrasse 487, Basel V8, 4058.

How can I contact Basilea Pharmaceutica?

Basilea Pharmaceutica's mailing address is Grenzacherstrasse 487, Basel V8, 4058. The company can be reached via phone at (161) 606-1111 or via email at [email protected]

This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.